Adamas Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.6M
Doctors Paid
4,478
Transactions
31,516
2021 Total
$1.1M
Payment Breakdown by Category
Research$10.6M (72.4%)
Food & Beverage$507,291 (3.5%)
Travel$334,001 (2.3%)
Consulting$124,055 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.6M | 3,350 | 72.4% |
| Honoraria | $2.9M | 1,405 | 20.0% |
| Food and Beverage | $507,291 | 25,015 | 3.5% |
| Travel and Lodging | $334,001 | 1,108 | 2.3% |
| Grant | $124,913 | 52 | 0.9% |
| Consulting Fee | $124,055 | 20 | 0.9% |
| Education | $4,915 | 566 | 0.0% |
Payments by Type
Research
$10.6M
3,350 transactions
General
$4.0M
28,166 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT | $7.4M | 0 | 1,946 |
| A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT | $2.8M | 0 | 1,343 |
| OPEN-LABEL SAFETY STUDY OF ADS-5102 AMANTADINE HCL EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA | $368,831 | 0 | 58 |
| OPEN-LABEL SAFETY STUDY OF ADS-5102 (AMANTADINE HCL) EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA | $6,463 | 0 | 1 |
| EFFICACY AND SAFETY OF ADS-5102 AMANTADINE HCL EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA IN PARKINSONS DISEASE PATIENTS EASE LID STUDY | $5,840 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Cherian Karunapuzha, Md, MD | Neurology | Oklahoma City, OK | $221,377 | $0 |
| Dr. Stuart Isaacson, Md, MD | Neurology | Boca Raton, FL | $208,591 | $0 |
| Dr. Salima Brillman, Md, MD | Psychiatry | Sunnyvale, CA | $147,543 | $0 |
| Dr. Michelle Dagostine, M.d, M.D | Neurology | Cheshire, CT | $134,721 | $0 |
| Khashayar Dashtipour, M.d, M.D | Neurology | Loma Linda, CA | $128,928 | $0 |
| Nirav Pavasia, M.d, M.D | Neurology | Dallas, TX | $115,974 | $0 |
| Unknown Provider | — | — | $111,659 | $0 |
| Dr. Zhigao Huang, Md, MD | Neurology | Jacksonville, FL | $109,567 | $0 |
| Dr. Robert Fekete, M.d, M.D | Neurology | Hawthorne, NY | $105,121 | $0 |
| Paula Ravin, M.d, M.D | Neurology | Los Angeles, CA | $96,175 | $0 |
| Dr. Duarte Machado, M.d, M.D | Student in an Organized Health Care Education/Training Program | Cheshire, CT | $95,842 | $0 |
| Dr. Laxman Bahroo, D.o,, D.O, | Neurology | Washington, DC | $93,212 | $0 |
| Dr. Mary Jean Stempien, M.d, M.D | Internal Medicine | San Francisco, CA | $92,948 | $0 |
| Pinky Agarwal, Md, MD | Specialist | Kirkland, WA | $84,056 | $0 |
| Dr. Ramon Rodriguez-Cruz, Md, MD | Neurology | Orlando, FL | $70,386 | $0 |
| Dr. Daniel Kremens, M.d., J.d, M.D., J.D | Neurology | Philadelphia, PA | $68,159 | $0 |
| Aaron Ellenbogen, D.o, D.O | Neurology | Farmington Hills, MI | $62,193 | $0 |
| Dr. Fahd Amjad, Md, MD | Neurology | Washington, DC | $60,734 | $0 |
| Sheila Baez-Torres, M.d, M.D | Neurology | Winter Park, FL | $59,701 | $0 |
| Dr. Sandeep Thakkar, D.o, D.O | Neurology | Irvine, CA | $56,408 | $0 |
| Dr. David Kreitzman, M.d, M.D | Neurology | Commack, NY | $53,535 | $0 |
| Robert Hauser, Md, MD | Neurology | Tampa, FL | $51,744 | $0 |
| Ramon Gil, Md, MD | Specialist | Port Charlotte, FL | $51,239 | $0 |
| Nisha Chhabria, Md, MD | Neurology | West Palm Beach, FL | $43,255 | $0 |
| Lin Zhang | Neurology | Sacramento, CA | $39,431 | $0 |
About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. has made $14.6M in payments to 4,478 healthcare providers, recorded across 31,516 transactions in the CMS Open Payments database. In 2021, the company paid $1.1M. The top product by payment volume is GOCOVRI ($3.9M).
Payments were distributed across 116 medical specialties. The top specialty by payment amount is Neurology ($3.0M to 2,690 doctors).
Payment categories include: Food & Beverage ($507,291), Consulting ($124,055), Research ($10.6M), Travel & Lodging ($334,001).
Adamas Pharmaceuticals, Inc. is associated with 2 products in the CMS Open Payments database.